These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29936685)

  • 1. Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.
    Bansal M; Shah M; Reilly B; Willman S; Gill M; Kaufman FR
    Appl Health Econ Health Policy; 2018 Oct; 16(5):675-684. PubMed ID: 29936685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
    Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
    J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
    Meng J; Casciano R; Lee YC; Stern L; Gultyaev D; Tong L; Kitio-Dschassi B
    J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes.
    Shetty S; Secnik K; Oglesby AK
    J Manag Care Pharm; 2005 Sep; 11(7):559-64. PubMed ID: 16137213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes.
    Fitch K; Pyenson BS; Iwasaki K
    J Manag Care Pharm; 2013 Oct; 19(8):609-20, 620a-620d. PubMed ID: 24074007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Costs, Hospital Admissions, and Glycemic Control Using a Standalone, Real-Time, Continuous Glucose Monitoring System in Commercially Insured Patients With Type 1 Diabetes.
    Gill M; Zhu C; Shah M; Chhabra H
    J Diabetes Sci Technol; 2018 Jul; 12(4):800-807. PubMed ID: 29737202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database.
    Lage MJ; Boye KS
    Curr Med Res Opin; 2020 Sep; 36(9):1441-1447. PubMed ID: 32643451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term cost analysis of complications related to glycated hemoglobin in patients with type 1 diabetes in the Italian setting.
    Nicolucci A; Buseghin G; De Portu S
    Acta Diabetol; 2016 Apr; 53(2):199-204. PubMed ID: 25943859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a Telephonic Intervention to Improve Diabetes Control on Health Care Utilization and Cost for Adults in South Bronx, New York.
    Tabaei BP; Howland RE; Gonzalez JS; Chamany S; Walker EA; Schechter CB; Wu WY
    Diabetes Care; 2020 Apr; 43(4):743-750. PubMed ID: 32132009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and economic impact of a diabetes education program among adults with type 2 diabetes in South Texas.
    Smith ML; Zhong L; Lee S; Towne SD; Ory MG
    BMC Public Health; 2021 Sep; 21(1):1646. PubMed ID: 34503468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levels of glycosylated hemoglobin and the difference in the cost of health care for diabetic patients: an econometric study].
    Lenz R; Zarate A; Rodríguez J; Ramírez J
    Rev Med Chil; 2014 Jul; 142(7):841-9. PubMed ID: 25378003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
    Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
    Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point-of-Care Hemoglobin A1c Testing: A Budget Impact Analysis.
    Chadee A; Blackhouse G; Goeree R
    Ont Health Technol Assess Ser; 2014; 14(9):1-23. PubMed ID: 26316923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Sustained Glycated Hemoglobin Control and Healthcare Costs.
    Juarez D; Goo R; Tokumaru S; Sentell T; Davis J; Mau M
    Am J Pharm Benefits; 2013; 5(2):59-64. PubMed ID: 24379909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of improved glycemic control on health care costs and utilization.
    Wagner EH; Sandhu N; Newton KM; McCulloch DK; Ramsey SD; Grothaus LC
    JAMA; 2001 Jan; 285(2):182-9. PubMed ID: 11176811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Points for improvement: performance measurement for glycemic control in diabetes patients in a safety-net population.
    Baxi S; Lakin J; Lyles CR; Berkowitz S; Horton C; Sarkar U
    Jt Comm J Qual Patient Saf; 2013 Mar; 39(3):109-13. PubMed ID: 23516760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program.
    Cranor CW; Christensen DB
    J Am Pharm Assoc (Wash); 2003; 43(2):160-72. PubMed ID: 12688434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between provider specialty and healthcare costs and glycemic control for patients with diabetes.
    Gill M; Chhabra H; Shah M; Zhu C; Lando H; Caldarella F
    J Med Econ; 2018 Jul; 21(7):704-708. PubMed ID: 29669452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control.
    Seinfeld J; Sobrevilla A; Rosales ML; Ibáñez M; Ruiz D; Penny E; Londoño S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):661-669. PubMed ID: 38584495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and costs of insulin pump therapy for diabetes.
    Ackermann RT; Wallia A; Kang R; Cooper A; Prospect TA; Sandy LG; Vojta D
    Am J Manag Care; 2017 Jun; 23(6):353-359. PubMed ID: 28817302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.